### Learner Notification

**Society of Gynecologic Oncology**

**2022 Welcoming Spaces**

**Enduring: March 29, 2022 – March 29, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

GSK Astra Zeneca

Seagen Merck

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians (ACCME) Credit Designation**

Amedco LLC designates this **enduring material** for a maximum of **1.0 Enduring**  *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of **1.0 Enduring** ANCC contact hours.

**Pharmacists and Pharmacy Technicians (ACPE) Credit Designation**

Amedco LLC designates this activity for a maximum of **1.0 Enduring** knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Identify the fundamental causes of health disparities in LGBTQ+ communities
2. Identify top health risks and related outcomes for this population
3. Explain and demonstrate how social determinants of health impact historically marginalized populations
4. Explore intersectionality and structural discrimination
5. Demonstrate how knowledge of socially determined health risks impact patient treatment and/or their healthcare experience

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Do you have any financial relationships with ineligible companies to disclose?** |
| Allison | Asante | Nothing to Disclose |
| Ethel Dawn | Capone | Nothing to Disclose |
| Monique | Gary | Nothing to Disclose |
| Cecilia | Hardacker | Nothing to Disclose |
| Bill | Jesdale | Nothing to Disclose |
| Teri | Jordan | Nothing to Disclose |
| Lisa | Kaszubski | Nothing to Disclose |
| Nina | Kennedy | Nothing to Disclose |
| Allison | Knuth | Nothing to Disclose |
| Angela | Kueck | Nothing to Disclose |
| Knoll | Larkin | Nothing to Disclose |
| Pam | Lewis | Nothing to Disclose |
| Phoenix | Matthews | Nothing to Disclose |
| Jennifer | Meade | Nothing to Disclose |
| Polly | Rossi | Nothing to Disclose |
| Karl | Surkan | Nothing to Disclose |
| Ana | Tergas | Nothing to Disclose |
| Christopher | Wheldon | Nothing to Disclose |
| Erin | Zink | Nothing to Disclose |
| Tracy | Sandstrom | Nothing to Disclose |
| Stephanie | Blank | Tesaro.GSK: Research Collaboration, Merck: Research Collaboration, Seattle Genetics: Research Collaboration, AstraZeneca: Research Collaboration, Roche: Research Collaboration |
| Don  | Dizon | Astra Zeneca: Consultant, Clovis: Consultant, Regeneron: Consultant, Pfizer: Consultant, Oasmia: Consultant |
| Aurea | Kasberg | Bristol Myers Squibb: Grant Recipient, Servier: Grant Recipient, GlaxoSmithKline: Grant Recipient, Genentech: Grant Recipient |
| BJ | Rimel | GSK: Advisory Board Participant, AstraZeneca: Advisory Board Participant, Deep6AI: Advisory Board Participant, Merck: Advisory Board Participant, Tempus: Consultant |
| NFN | Scout | Syros Pharmaceuticals: Grant Recipient, Servier Pharmaceuticals: Grant Recipient, Bristol Myers Squibb: Grant Recipient, Glaxo Smith Klein: Grant Recipient, Genentech: Grant Recipient |